There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do not inform patients of the risks associated with these medicines, according to a research letter published on Friday.

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. | In the phase 3b STEP UP study,

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. The big pharma companies Novo Nordisk and Eli Lilly look to be the main benefactors of GLP-1 medications turning into a “catch-all pill,

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s tirzepati | An observational study from Washington University in St.

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.

ABC News chief medical correspondent Dr. Tara Narula explains the findings of a new study on GLP-1 drugs commonly used for weight loss.

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart disease, and obesity. Commonly marketed under brand names like Ozempic and Wegovy,